기본 통계
| LEI | 549300395G8DB8ZFV365 |
| CIK | 1372514 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kiora Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 28, 2026 |
PROSPECTUS KIORA PHARMACEUTICALS, INC. 11,797,088 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-295994 PROSPECTUS KIORA PHARMACEUTICALS, INC. 11,797,088 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling stockholders identified in this prospectus of up to (i) 438,471 shares of our common stock, par value $0.01 per share (the “Common Stock”), initially issued in a private placement on A |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
Exhibit FILING FEES Calculation of Filing Fee Tables FORM S-3 ………….. (Form Type) KIORA PHARMACEUTICALS, INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offerin |
|
| May 8, 2026 |
Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Encinitas, CA - May 8, 2026 - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA PHA |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2026 KIORA PHARMACEUTICALS, INC. |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA PHARMACEUTIC |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐Confiden |
|
| April 7, 2026 |
KIORA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 3, 2026 KIORA PHARMACEUTICALS, INC. |
|
| April 7, 2026 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 3, 2026, by and among Kiora Pharmaceuticals, Inc. |
|
| April 7, 2026 |
Exhibit 99.1 Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million led by Perceptive Advisors Sole investors are Perceptive Advisors (new) and ADAR1 Capital Management Encinitas, California, April 7, 2026 — Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) (the “Company”), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting |
|
| April 7, 2026 |
KIORA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| April 7, 2026 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 6, 2026, is entered into by and among Kiora Pharmaceuticals, Inc. |
|
| April 7, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT KIORA PHARMACEUTICALS, INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| April 2, 2026 |
Kiora Pharmaceuticals Announces Management Team Changes Exhibit 99.1 Kiora Pharmaceuticals Announces Management Team Changes Encinitas, California — April 2, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D., MBA, will depart from his role as Chief Development Officer on April 17, 2026, to pursue other opportunities. The Company has initiated a search for his successor. “Eric has mad |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 1, 2026 KIORA PHARMACEUTICALS, INC. |
|
| March 25, 2026 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials Encinitas, California — March 25, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end b |
|
| March 25, 2026 |
Exhibit FILING FEES Calculation of Filing Fee Tables FORM S-8 ………….. (Form Type) KIORA PHARMACEUTICALS, INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Off |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2026 KIORA PHARMACEUTICALS, INC. |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 |
|
| March 25, 2026 |
KIORA PHARMACEUTICALS, INC. CODE OF ETHICS AND BUSINESS CONDUCT KIORA PHARMACEUTICALS, INC. CODE OF ETHICS AND BUSINESS CONDUCT Adopted by the Board of Directors on September 12, 2014 Amended effective November 8, 2021 1.POLICY STATEMENT The reputation and integrity of Kiora Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company”) are valuable assets that are vital to the Company's success. Operating with integrity is critical to maintaining th |
|
| March 25, 2026 |
As filed with the Securities and Exchange Commission on March 25, 2026 As filed with the Securities and Exchange Commission on March 25, 2026 Commission File No. |
|
| November 7, 2025 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases Encinitas, California – November 7, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update on its pipeline of small molecules for th |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 7, 2025 KIORA PHARMACEUTICALS, INC. |
|
| September 19, 2025 |
X0101 EFFECT 33 LIVE 2025-09-19 16:30:00 S-3 0001372514 KIORA PHARMACEUTICALS INC 333-290263 |
|
| September 17, 2025 |
Kiora Pharmaceuticals, Inc. 169 Saxony Road, Suite 212 Encinitas, California 92024 Kiora Pharmaceuticals, Inc. 169 Saxony Road, Suite 212 Encinitas, California 92024 September 17, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-290263 Request for Acceleration Ladies and Gentlemen: In accordance |
|
| September 16, 2025 |
September 16, 2025 Brian M. Strem Chief Executive Officer Kiora Pharmaceuticals, Inc. 169 Saxony Rd. Suite 212 Encinitas, CA 92024 Re: Kiora Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed September 15, 2025 File No. 333-290263 Dear Brian M. Strem: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regar |
|
| September 15, 2025 |
KIORA PHARMACEUTICALS, INC. DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS EXHIBIT 4.1 KIORA PHARMACEUTICALS, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE One. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 11 SECTION 103. Form of Documents Delivered to Trustee 12 SECTION 104. Acts of Holders 12 SECTION 105. Noti |
|
| September 15, 2025 |
KIORA PHARMACEUTICALS, INC. DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS EXHIBIT 4.2 KIORA PHARMACEUTICALS, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 101. Definitions 2 Section 102. Compliance Certificates and Opinions 11 Section 103. Form of Documents Delivered to Trustee 12 Section 104. Acts of Holders 12 Section 105 |
|
| September 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) KIORA PHARMACEUTICALS, INC. |
|
| September 15, 2025 |
As filed with the Securities and Exchange Commission on September 15, 2025 As filed with the Securities and Exchange Commission on September 15, 2025 Registration No. |
|
| August 13, 2025 |
kiorapharmaoverviewq3202 Kiora Pharmaceuticals, Inc. NASDAQ: KPRX 13 Aug 2025 | Corporate Overview H.C. Wainwright 5th Annual Ophthalmology Virtual Conference 2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements inc |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2025 KIORA PHARMACEUTICALS, INC. |
|
| August 8, 2025 |
ddendum to Credit Line Agreement, dated as of March 18, 2025, by and between Ki addendumtocreditlineagre |
|
| August 8, 2025 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Encinitas, California – August 8, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 8, 2025 KIORA PHARMACEUTICALS, INC. |
|
| August 8, 2025 |
, dated as of March 12, 2025, by and between Kiora Pharmaceu creditlineagreement |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA PHAR |
|
| July 1, 2025 |
July 1, 2025 Melissa Tosca Chief Financial Officer Kiora Pharmaceuticals, Inc. 332 Encinitas Blvd., Suite 102 Encinitas, CA 92024 Re: Kiora Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 25, 2025 File No. 001-36672 Dear Melissa Tosca: We have completed our review of your filing. We remind you that the company and its management are responsible for the accur |
|
| June 20, 2025 |
seccommentletter-kiorare June 20, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D. |
|
| June 10, 2025 |
June 10, 2025 Melissa Tosca Chief Financial Officer Kiora Pharmaceuticals, Inc. 332 Encinitas Blvd., Suite 102 Encinitas, CA 92024 Re: Kiora Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 25, 2025 File No. 001-36672 Dear Melissa Tosca: We have limited our review of your filing to the financial statements and related disclosures and have the following commen |
|
| June 4, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2025 KIORA PHARMACEUTICALS, INC. |
|
| June 3, 2025 |
Exhibit 99.1 Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia –Total potential deal value of $110 million plus royalties –Kiora to receive an immediate $1.25 million exclusive option fee –If the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory, and commercial miles |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 30, 2025 KIORA PHARMACEUTICALS, INC. |
|
| June 3, 2025 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA PHA |
|
| May 9, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2025 KIORA PHARMACEUTICALS, INC. |
|
| May 9, 2025 |
Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 Encinitas, California – May 9, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pip |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐Confiden |
|
| March 25, 2025 |
Calculation of Registration Fee. Exhibit FILING FEES Calculation of Filing Fee Tables FORM S-8 ………….. (Form Type) KIORA PHARMACEUTICALS, INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Off |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Commission File No. |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2025 KIORA PHARMACEUTICALS, INC. |
|
| March 25, 2025 |
Kiora Pharmaceuticals, Inc. Clawback Policy Exhibit 97.1 KIORA PHARMACEUTICALS, INC. CLAWBACK POLICY 1.Introduction The Board of Directors (the “Board”) of the Kiora Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The B |
|
| March 25, 2025 |
Exhibit 99.1 Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-term Investments Expected to Fund Operations into 2027 Encinitas, California - March 25, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics |
|
| March 25, 2025 |
Exhibit 19.1 Insider Trading Policy This Insider Trading Policy (the “Policy”) provides guidelines to employees, officers and directors of Kiora Pharmaceuticals, Inc. (the “Company”) with respect to transactions in the Company’s securities. Applicability of the Policy This Policy applies to all transactions in the securities of the Company or certain other publicly traded companies, including comm |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 |
|
| February 12, 2025 |
EX-99 2 POA13G-150007215320250128.txt EXHIBIT 99 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that THE GOLDMAN SACHS GROUP, INC. (the "Company") does hereby make, constitute and appoint Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, |
|
| February 10, 2025 |
EX-99.A BD-DIR-RESOL 2 rosalindkprxexamay202.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of KIORA PHARMACEUTICALS INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDo |
|
| January 15, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2025 KIORA PHARMACEUTICALS, INC. |
|
| January 15, 2025 |
KIORA PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT KIORA PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, entered into as of January 10, 2025 (this “Agreement”), is made by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Employer”), and Eric J. Daniels, MD, MBA (the “Employee”) (Employer and Employee collectively, the “Parties”). WHEREAS, the Employer desires to employ the Employee and the Employee desire |
|
| January 15, 2025 |
Employment Agreement by and between Kiora Pharmaceuticals, Inc. and KIORA PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, entered into as of January 10, 2025 (this “Agreement”), is made by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Employer”), and Melissa Tosca, CPA (the “Employee”) (Employer and Employee collectively, the “Parties”). WHEREAS, the Employer desires to employ the Employee and the Employee desires to b |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.01 per share, of Kiora Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to s |
|
| November 14, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / ADAR1 Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm2428381d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49721T507 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Ch |
|
| November 14, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G 1 alyeska-kprx093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KIORA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 49721T507 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 14, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49721T507 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| November 13, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 kprx13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49721T507 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 12, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / GOLDMAN SACHS GROUP INC Passive Investment SC 13G 1 KIORA.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KIORA PHARMACEUTICALS INC - (Name of Issuer) Common Stock, par value $0.01 per share - (Title of Class of Securities) 49721T507 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2024 KIORA PHARMACEUTICALS, INC. |
|
| November 8, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California – November 8, 2024 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter a |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KI |
|
| October 29, 2024 |
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California – October 29, 2024 - Kiora Pharmaceuticals, Inc. |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2024 KIORA PHARMACEUTICALS, INC. |
|
| October 29, 2024 |
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Q4 2024 | Corporate Overview 2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization ef |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA P |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2024 KIORA PHARMACEUTICALS, INC. |
|
| August 9, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Encinitas, California - August 9, 2024 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on its pipeline of therapeutics for the treatment of retinal diseases. D |
|
| July 30, 2024 |
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies Encinitas, CA – July 30, 2024 – Kiora Pharmaceuticals (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced it has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of a group of inherited retinal diseases (IRDs) that include retinitis pigmentosa (RP), choroideremia and more. |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2024 KIORA PHARMACEUTICALS, INC. |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 28, 2024 KIORA PHARMACEUTICALS, INC. |
|
| July 1, 2024 |
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors •Ken Gayron to Step Down as a Member of the Company’s Board July 1, 2024 - Encinitas, California - Kiora Pharmaceuticals, Inc. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2024 KIORA PHARMACEUTICALS, INC. |
|
| June 7, 2024 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION Pursuant to Section 242 of the General Corporation Law of the State of Delaware Kiora Pharmaceuticals, Inc. |
|
| May 29, 2024 |
EX-99.A BD-DIR-RESOL 2 rosalindkprxexamay202.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of KIORA PHARMACEUTICALS INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDo |
|
| May 29, 2024 |
US49721T1016 / KIORA PHARMACEUTICALS INC / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KIORA PHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 49721T101 (CUSIP Number) March 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| May 29, 2024 |
US49721T1016 / KIORA PHARMACEUTICALS INC / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KIORA PHARMACEUTICALS INC. (Name of Issuer) Common Shares (Title of Class of Securities) 49721T101 (CUSIP Number) March 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| May 29, 2024 |
EX-99.A BD-DIR-RESOL 2 rosalindkprxexamay202.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of KIORA PHARMACEUTICALS INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDo |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Commission File No. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2024 KIORA PHARMACEUTICALS, INC. |
|
| May 10, 2024 |
Calculation of Registration Fee. Exhibit 107 Calculation of Filing Fee Tables FORM S-8 ………….. (Form Type) KIORA PHARMACEUTICALS, INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| May 10, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and ca |
|
| May 3, 2024 |
Certificate of Amendment to Restated Certificate of Incorporation CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION Pursuant to Section 242 of the General Corporation Law of the State of Delaware Kiora Pharmaceuticals, Inc. |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 1, 2024 KIORA PHARMACEUTICALS, INC. |
|
| March 28, 2024 |
KIORA PHARMACEUTICALS, INC. 76,528,829 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-277460 PROSPECTUS KIORA PHARMACEUTICALS, INC. 76,528,829 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling stockholders identified in this prospectus of up to (i) 15,800,000 shares of our common stock, par value $0.01 per share (the “Common Stock”), initially issued in a private placement o |
|
| March 26, 2024 |
Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 March 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-277460 Request for Acceleration Ladies and Gentlemen: In accorda |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2024 KIORA PHARMACEUTICALS, INC. |
|
| March 25, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases; Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California - March 25, 2024 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2023 financial results and provided an update on its reti |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐Confiden |
|
| March 25, 2024 |
KIORA PHARMACEUTICALS, INC. CLAWBACK POLICY 1.Introduction The Board of Directors (the “Board”) of the Kiora Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has ther |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐Confiden |
|
| March 4, 2024 |
United States securities and exchange commission logo March 4, 2024 Brian Strem, Ph. |
|
| February 28, 2024 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) KIORA PHARMACEUTICALS, INC. |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 14, 2024 |
EX-99.1 2 tm246286d1ex-1.htm EXHIBIT 1 EXHIBIT 99.1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completenes |
|
| February 14, 2024 |
SC 13G/A 1 tm246286d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* KIORA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 49721T101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.01 per share, of Kiora Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to s |
|
| February 13, 2024 |
US49721T3095 / Kiora Pharmaceuticals Inc / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49721T309 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 12, 2024 KIORA PHARMACEUTICALS, INC. |
|
| February 12, 2024 |
kiorapharmaoverviewh1202 Kiora Pharmaceuticals, Inc. NASDAQ: KPRX H1 2024 | Corporate Overview 2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development |
|
| February 9, 2024 |
US49721T3095 / Kiora Pharmaceuticals Inc / Stonepine Capital Management, LLC Passive Investment SC 13G 1 kiora13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49721T309 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 7, 2024 |
KPRX / Kiora Pharmaceuticals, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49721T1309 (CUSIP Number) February 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 49721T1309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 1, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million $15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in total gross proceeds ENCINITAS, Calif., Jan. 31, 2024 /Newsfile Corp./ - Kiora Pharmaceuticals, Inc |
|
| February 1, 2024 |
exhibit43-formoftrancheb 1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 1, 2024 |
exhibit102-placementagen EXECUTION VERSION PLACEMENT AGENCY AGREEMENT January 31, 2024 Brian M. |
|
| February 1, 2024 |
exhibit41-formofprexfund NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 1, 2024 |
exhibit42-formoftranchea 1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 1, 2024 |
exhibit101-securitiespur EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 31, 2024, between Kiora Pharmaceuticals, Inc. |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 31, 2024 KIORA PHARMACEUTICALS, INC. |
|
| January 31, 2024 |
ex101-exclusivelicensean 1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| January 31, 2024 |
Exhibit 99.1 Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties - Kiora to webcast investor conference call at 5:30 |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 25, 2024 KIORA PHARMACEUTICALS, INC. |
|
| January 31, 2024 |
ex992-companypresentatio Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Strategic Collaboration with Théa | January 31, 2024 2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2024 KIORA PHARMACEUTICALS, INC. |
|
| November 9, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| November 9, 2023 |
Kiora Pharmaceu-cals, Inc. NASDAQ: KPRX Q4 2023 | Corporate Overview 2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization eff |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 KIORA PHARMACEUTICALS, INC. |
|
| November 9, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa Encinitas, California - November 9, 2023 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing an update |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KI |
|
| November 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 KIORA PHARMACEUTICALS, INC. |
|
| November 9, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2023 KIORA PHARMACEUTICALS, INC. |
|
| November 6, 2023 |
Exhibit 99.1 AAO Late-Breaking: Kiora’s Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa Topline Phase I/II First-in-Human Results Presented at AAO 2023 Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision Functional MRI demonstrates increased brain activity in visu |
|
| October 13, 2023 |
As filed with the Securities and Exchange Commission on October 13, 2023 As filed with the Securities and Exchange Commission on October 13, 2023 Registration No. |
|
| October 13, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 ………….. (Form Type) KIORA PHARMACEUTICALS, INC. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| September 28, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2023 KIORA PHARMACEUTICALS, INC. |
|
| September 21, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years September 21, 2023 - Encinitas, CA - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who i |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 20, 2023 KIORA PHARMACEUTICALS, INC. |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐Confiden |
|
| September 1, 2023 |
Press Release of Kiora Pharmaceuticals, Inc., dated as of September 1, 2023 Exhibit 99.1 Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 Encinitas, CA – September 1, 2023 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) announced that the Company’s Special Meeting of Stockholders (the “Special Meeting”) held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, d |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2023 KIORA PHARMACEUTICALS, INC. |
|
| September 1, 2023 |
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 Exhibit 99.1 Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 Encinitas, CA – September 1, 2023 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) announced that the Company’s Special Meeting of Stockholders (the “Special Meeting”) held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, d |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA P |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 8, 2023 KIORA PHARMACEUTICALS, INC. |
|
| August 8, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress –Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023 –Data Sup |
|
| August 1, 2023 |
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors Exhibit 99.1 Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors August 1, 2023 - Encinitas, California - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company’s board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics, a company developing precision medicines to treat neu |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2023 KIORA PHARMACEUTICALS, INC. |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐Confiden |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2023 KIORA PHARMACEUTICALS, INC. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐Confiden |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 21, 2023 KIORA PHARMACEUTICALS, INC. |
|
| June 15, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 •Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx •Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary use •Kiora will receive a royalty on net sales of products covered by lic |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 12, 2023 KIORA PHARMACEUTICALS, INC. |
|
| June 15, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| June 15, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| June 13, 2023 |
US49721T3095 / Kiora Pharmaceuticals Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 49721T309 (CUSIP Number) June 6, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| June 13, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.01 per share, of Kiora Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. June 13, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners II L |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2023 KIORA PHARMACEUTICALS, INC. |
|
| June 6, 2023 |
Exhibit 99.2 Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Encinitas, California-(Newsfile Corp. – June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full |
|
| June 6, 2023 |
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering Exhibit 99.1 Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering Encinitas, California-(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions and of |
|
| June 6, 2023 |
2023, by and between Kiora Pharmaceuticals, Inc. and VStock Transfer, LLC Exhibit 4.3 KIORA PHARMACEUTICALS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of June 6, 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June 6, 2023 (“Agreement”), by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a New York limited liability trust company (“VStock” or the “Warra |
|
| June 6, 2023 |
Exhibit 1.1 1,447,628 SHARES OF COMMON STOCK, 3,908 SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO 3,552,372 SHARES OF COMMON STOCK) AND 5,000,000 CLASS C WARRANTS (EXERCISABLE FOR 5,000,000 SHARES OF COMMON STOCK) 5,000,000 CLASS D WARRANTS (EXERCISABLE FOR 5,000,000 SHARES OF COMMON STOCK) OF KIORA PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT June 2, 2023 Ladenburg Thalmann & C |
|
| June 6, 2023 |
Exhibit 3.1 KIORA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Brian M. Strem, Ph.D., does hereby certify that: 1. He is the President, Chief Executive Officer and Secretary of Kiora Pharmaceuticals, Inc., a Delaware corporation (the “C |
|
| June 2, 2023 |
Filed Pursuant to Rule 424(b)(1) Registration No. 333-271699 PROSPECTUS 1,447,628 Shares of Common Stock 3,908 Shares of Series F Convertible Preferred Stock (3,552,372 shares of Common Stock underlying the Series F Convertible Preferred Stock) Class C Warrants to Purchase up to 5,000,000 Shares of Common Stock (5,000,000 shares of Common Stock underlying the Class C Warrants) and Class D Warra |
|
| June 1, 2023 |
Exhibit 4.13 CLASS D COMMON STOCK PURCHASE WARRANT KIORA PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS CLASS D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| June 1, 2023 |
Exhibit 4.12 CLASS C COMMON STOCK PURCHASE WARRANT KIORA PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS CLASS C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on May 31, 2023 S-1/A 1 kiorapharmaceuticalsinc-sx.htm S-1/A As filed with the Securities and Exchange Commission on May 31, 2023 Registration No. 333-271699 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kiora Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 2834 98-04 |
|
| June 1, 2023 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables FORM S-1/A (Form Type) KIORA PHARMACEUTICALS, INC. |
|
| June 1, 2023 |
Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc. Exhibit 1.1 SHARES OF COMMON STOCK, SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO SHARES OF COMMON STOCK) AND CLASS C WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) CLASS D WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) OF KIORA PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT , 2023 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named |
|
| June 1, 2023 |
Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC Exhibit 4.14 KIORA PHARMACEUTICALS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2023 (“Agreement”), by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a New York limited liability trust company (“VStock” or the “Warrant Agent”). |
|
| May 31, 2023 |
Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 May 31, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-271699 Request for Acceleration Ladies and Gentlemen: In accordanc |
|
| May 31, 2023 |
s1concurrinaccelreq0531 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 May 31, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: Kiora Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-271699) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenbur |
|
| May 31, 2023 |
s1accelerationrequest05 Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 May 31, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-271699 Request for Acceleration Ladies and |
|
| May 24, 2023 |
s1concurrinaccelreq0520 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 May 24, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: Kiora Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-271699) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenbur |
|
| May 24, 2023 |
Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 May 24, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-271699 Request for Acceleration Ladies and Gentlemen: Reference is |
|
| May 23, 2023 |
s1accelerationrequest05 Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 May 23, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-271699 Request for Acceleration Ladies and |
|
| May 15, 2023 |
q22023kiorapharmaovervi Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Q2 2023 | Corporate Overview Filed pursuant to Rule 433 under the Securities Act of 1933, as amended Dated 5/15/2023 Registration Statement No. 333-271699 2 Forward Looking Statements Some of the statements in this presentation are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigati |
|
| May 12, 2023 |
Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC Exhibit 4.13 KIORA PHARMACEUTICALS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2023 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2023 (“Agreement”), by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a New York limited liability trust company (“VStock” or the “Warrant Agent”). |
|
| May 12, 2023 |
Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc. Exhibit 1.1 SHARES OF COMMON STOCK, SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO SHARES OF COMMON STOCK) AND WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) OF KIORA PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT , 2023 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 640 Fifth Avenue, 4th Floor New York, New Yo |
|
| May 12, 2023 |
Exhibit 3.13 KIORA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Brian M. Strem, Ph.D., does hereby certify that: 1. He is the President, Chief Executive Officer and Secretary of Kiora Pharmaceuticals, Inc., a Delaware corporation (the “ |
|
| May 12, 2023 |
Form of Common Stock Purchase Warrant Exhibit 4.12 CLASS C COMMON STOCK PURCHASE WARRANT KIORA PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS CLASS C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| May 12, 2023 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables FORM S-1/A (Form Type) KIORA PHARMACEUTICALS, INC. |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 9, 2023 |
United States securities and exchange commission logo May 9, 2023 Brian M. Strem, Ph.D. President and Chief Executive Officer Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 Re: Kiora Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 5, 2023 File No. 333-271699 Dear Brian M. Strem: This is to advise you that we have not reviewed and will |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KIORA |
|
| May 9, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments Encinitas, CA - May 9, 2023 - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2023 KIORA PHARMACEUTICALS, INC. |
|
| May 5, 2023 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) KIORA PHARMACEUTICALS, INC. |
|
| May 5, 2023 |
As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confident |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2023 KIORA PHARMACEUTICALS, INC. |
|
| April 27, 2023 |
Exhibit 99.1 Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind Encinitas, California, April 27, 2023 – Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blin |
|
| March 30, 2023 |
Exhibit 16.1 March 30, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated March 30, 2023 of Kiora Pharmaceuticals, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01. Sin |
|
| March 30, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 24, 2023 KIORA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36672 98-0443284 (Commiss |
|
| March 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 23, 2023 KIORA PHARMACEUTICALS, INC. |
|
| March 23, 2023 |
Exhibit 99.1 Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress March 23, 2023 - Encinitas, CA - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022. CEO Commentary: “In 2022, we advanced our pipeline of three differentiate |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 |
|
| February 14, 2023 |
US49721T3095 / Kiora Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING APPLICATION The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value $0.01 per share, of Kiora Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit t |
|
| February 13, 2023 |
SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 49721T309 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING APPLICATION The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value $0.01 per share, of Kiora Pharmaceuticals, Inc.shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| February 13, 2023 |
Up to 1,052,798 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269570 PROSPECTUS Up to 1,052,798 Shares of Common Stock This prospectus relates to the offer and sale of up to 1,052,798 shares of our Common Stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of Common Stock to which this prospectus r |
|
| February 13, 2023 |
SC 13G 1 sc13ga.htm (AMENDMENT NO. 1)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 49721T309 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) |
|
| February 9, 2023 |
Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 CORRESP 1 filename1.htm Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 February 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-269570 Request for Acceleration Ladies |
|
| February 9, 2023 |
United States securities and exchange commission logo February 9, 2023 Brian Strem Chief Executive Officer KIORA PHARMACEUTICALS INC 332 Encinitas Boulevard, Suite 102 Encinitas, CA 92024 Re: KIORA PHARMACEUTICALS INC Registration Statement on Form S-1 Filed February 3, 2023 File No. |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 49721T1309 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 7, 2023 KIORA PHARMACEUTICALS, INC. |
|
| February 7, 2023 |
EX-99.1 2 ex991-pressreleasekiox101p.htm EX-99.1 Exhibit 99.1 Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases Encinitas, California — February 07, 2023 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 st |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 3, 2023 KIORA PHARMACEUTICALS, INC. |
|
| February 3, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 2, 2023, is by and among Kiora Pharmaceuticals, Inc., a Delaware corporation (the ”Company”), and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (the “Buyer”). RECITALS A. The Buyer wishes to purchase, and the Company wishes to sell, upon the terms and subje |
|
| February 3, 2023 |
EX-4.1 2 a8-klpcf020323exhibit41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR |
|
| February 3, 2023 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Kiora Pharmaceuticals, Inc. |
|
| February 3, 2023 |
As filed with the Securities and Exchange Commission on February 3, 2023 As filed with the Securities and Exchange Commission on February 3, 2023 Registration No. |
|
| February 3, 2023 |
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital Exhibit 99.1 Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital ENCINITAS, CA, February 3, 2023 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today announced that it has entered into a common stock purchase agreement for a committed equity financing (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), a long-stan |
|
| February 3, 2023 |
EX-10.4 6 a8-klpcf020323exhibit104.htm EX-10.4 Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 3, 2023, by and between KIORA PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms use |
|
| February 3, 2023 |
Exhibit 10.3 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2023, by and between KIORA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and th |
|
| February 3, 2023 |
EX-10.2 4 a8-klpcf020323exhibit102.htm EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 2, 2023, by and between KIORA PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). WHEREAS: A. In connection with the Securities Purchase Ag |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 9, 2023 KIORA PHARMACEUTICALS, INC. |
|
| January 9, 2023 |
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX January 2023 | Corporate Outlook Exhibit 99.1 Kiora Pharmaceuticals, Inc. NASDAQ: KPRX January 2023 | Corporate Outlook 2 Forward Looking Statements Some of the statements in this presentation are “forward - looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These “forward - looking” statements include statements relating to, among other things, the development an |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 1, 2023 KIORA PHARMACEUTICALS, INC. |
|
| December 28, 2022 |
654,610 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-268940 PROSPECTUS 654,610 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling stockholders identified in this prospectus of up to 654,610 shares of our common stock, par value $0.01 per share (the ?Common Stock?), that are issuable upon exercise of presently issued and outstanding warrants to |
|
| December 23, 2022 |
Kiora Pharmaceuticals, Inc. 1371 East 2100 South, Suite 200 Salt Lake City, Utah 84105 Kiora Pharmaceuticals, Inc. 1371 East 2100 South, Suite 200 Salt Lake City, Utah 84105 December 23, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kiora Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-268940 Request for Acceleration Ladies and Gentlemen: In accordan |
|
| December 23, 2022 |
United States securities and exchange commission logo December 23, 2022 Brian M. Strem, Ph.D. Chief Executive Officer Kiora Pharmaceuticals, Inc. 1371 East 2100 South, Suite 200 Salt Lake City, UT 84105 Re: Kiora Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 22, 2022 File No. 333-268940 Dear Brian M. Strem: This is to advise you that we have not reviewed and will not revi |
|
| December 22, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 S-1 1 tm2233181d1s1.htm S-1 As filed with the Securities and Exchange Commission on December 21, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kiora Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 2834 98-0443284 (State or other jurisdiction of |
|
| December 22, 2022 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Tables FORM S-1 ????.. (Form Type) KIORA PHARMACEUTICALS, INC. ????????????????????..? (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering P |
|
| November 21, 2022 |
Exhibit 10.1 November 17, 2022 [Name and address of warrant holder] Re: Reprice and Reload Offer of Class A Common Stock Purchase Warrants To Whom It May Concern: Kiora Pharmaceuticals, Inc. (the “Company”) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of the Class A Common Stock purchase warrants set forth |
|
| November 21, 2022 |
Exhibit 99.1 Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants Salt Lake City, Utah-(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it has entered into warrant inducement offer letters to raise $3.12 million in gross proceeds from the exercise of 65 |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 17, 2022 KIORA PHARMACEUTICALS, INC. |
|
| November 21, 2022 |
424B3 1 tm2230974d1424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-264641 PROSPECTUS SUPPLEMENT NO. 1 DATED NOVEMBER 21, 2022 (To Prospectus dated July 22, 2022) KIORA PHARMACEUTICALS, INC. 592,392 Shares of Common Stock, 1,280 Shares of Series E Convertible Preferred Stock (160,000 shares of Common Stock underlying the Series E Convertible Preferred Stock), Class A Warrants |
|
| November 21, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36672 KI |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2022 KIORA PHARMACEUTICALS, INC. |
|
| October 13, 2022 |
Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Salt Lake City, Utah-(October 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC (“Nasdaq”) on October 12, 2022 informing Kiora that it has regained compliance with the minimum bid |
|
| October 5, 2022 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 ????.. (Form Type) KIORA PHARMACEUTICALS, INC. ????????????????????..? (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| September 26, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION ? Pursuant to Section 242 of the General Corporation Law of the State of Delaware Kiora Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: The name of the Corporation is Kiora |
|
| September 26, 2022 |
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split Exhibit 99.1 Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split Salt Lake City, Utah - (September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company?s common stock. Following the annual stockholder meeting, the board of directors approved a reverse stock split of one share of commo |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2022 KIORA PHARMACEUTICALS, INC. |
|
| September 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2022 KIORA PHARMACEUTICALS, INC. |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2022 KIORA PHARMACEUTICALS, INC. |
|
| September 16, 2022 |
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Exhibit 99.1 Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Salt Lake City, Utah-(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting fun |
|
| September 16, 2022 |
Exhibit 10.1 August 17, 2022 Melissa Tosca Dear Melissa: Kiora Pharmaceuticals, Inc. (the ?Company?) is pleased to offer you employment with a start date of September 13, 2022. Your role shall be to serve as Executive Vice President Finance of the Company. This letter is intended to summarize some of the terms of your employment. We refer you to the policies, plans and practices of the Company for |
|
| August 25, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 23, 2022 KIORA PHARMACEUTICALS, INC. |
|
| August 15, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminar |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminar |
|
| August 5, 2022 |
US49721T1016 / KIORA PHARMACEUTICALS INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiora Pharmaceuticals, Inc. (Name of Issuer) Common Shares, $0.01 par value per share (Title of Class of Securities) 49721T101 (CUSIP Number) July 26, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
